Key result
Oral anticoagulant type shows no association with recurrent stroke or systemic embolism after AF-related stroke.
Why the study?
Evidence is lacking regarding the optimal therapeutic approach for patients who experience recurrent stroke while receiving anticoagulation.
Does the type of oral anticoagulant affect the risk of recurrent ischemic stroke, TIA, or systemic embolism in patients with atrial fibrillation-related stroke?
Population
60 patients treated in the stroke unit for AF-related stroke
Comparison
Recurrent vs non-recurrent stroke groups across types of oral anticoagulant
Design
Cross-sectional study
Authors
Loading...
Should not yet alter anticoagulant choice in AF-related stroke; leaves open optimal dosing and recurrence risks for prospective study.
Does the type of oral anticoagulant affect the risk of recurrent ischemic stroke, TIA, or systemic embolism in patients with atrial fibrillation-related stroke?
In patients with atrial fibrillation-related stroke, the type of oral anticoagulant was not associated with recurrence, though underdosing and subtherapeutic levels were prevalent.
Sánchez-Acosta et al. (2023) studied this question. The type of oral anticoagulant was not associated with recurrent ischemic stroke, TIA, or systemic embolism in 60 patients with a prior atrial fibrillation-related stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: